- Home
- IONS vs OSK Comparison
IONS vs OSK Comparison
Compare IONS & OSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- OSK
- Stock Information
- Founded
- IONS 1989
- OSK 1917
- Country
- IONS United States
- OSK United States
- Employees
- IONS N/A
- OSK N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- OSK Auto Manufacturing
- Sector
- IONS Health Care
- OSK Consumer Discretionary
- Exchange
- IONS Nasdaq
- OSK Nasdaq
- Market Cap
- IONS 5.4B
- OSK 5.6B
- IPO Year
- IONS 1991
- OSK N/A
- Fundamental
- Price
- IONS $33.51
- OSK $99.22
- Analyst Decision
- IONS Buy
- OSK Buy
- Analyst Count
- IONS 18
- OSK 14
- Target Price
- IONS $57.41
- OSK $114.93
- AVG Volume (30 Days)
- IONS 1.5M
- OSK 707.4K
- Earning Date
- IONS 04-30-2025
- OSK 04-30-2025
- Dividend Yield
- IONS N/A
- OSK 2.06%
- EPS Growth
- IONS N/A
- OSK N/A
- EPS
- IONS N/A
- OSK 9.37
- Revenue
- IONS $717,253,000.00
- OSK $10,499,200,000.00
- Revenue This Year
- IONS $7.14
- OSK N/A
- Revenue Next Year
- IONS $18.89
- OSK $4.94
- P/E Ratio
- IONS N/A
- OSK $10.59
- Revenue Growth
- IONS N/A
- OSK 5.69
- 52 Week Low
- IONS $23.95
- OSK $76.82
- 52 Week High
- IONS $52.34
- OSK $118.39
- Technical
- Relative Strength Index (RSI)
- IONS 56.80
- OSK 57.51
- Support Level
- IONS $32.00
- OSK $96.03
- Resistance Level
- IONS $33.65
- OSK $101.09
- Average True Range (ATR)
- IONS 1.08
- OSK 2.13
- MACD
- IONS -0.10
- OSK -0.02
- Stochastic Oscillator
- IONS 55.72
- OSK 43.81
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About OSK Oshkosh Corporation (Holding Company)Common Stock
Oshkosh Corp is the top producer of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, where it is typically the market share leader in North America, or, in the case of JLG aerial work platforms. The company had manufactured joint light tactical vehicles for the U.S. Department of Defense. The company reports in three segments: Access, Vocational and Defense. It derives maximum revenue from Access Segment.